Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Presenters will review resources available to rural grantees through their respective organizations.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 3/25/2021 (updated 4/5/2024)
Federal Resources: A Virtual Tour
Presenters will review resources available to rural grantees through their respective organizations.
Christina Mead, PharmD, Regional Pharmacy Consultant, U.S. Public Health Service, U.S. Department of Health and Human Services/HRSA/Office of Regional Operations
Kristin Martinsen, MPA, Director, Hospital State Division, FORHP, HRSA
Betty-Ann Bryce, JD, MPA, Special Advisor for Rural Affairs, Office of National Drug Control Policy
Humberto Carvalho, MPH, Grants Project Manager, Substance Abuse and Mental Health Services Administration
Posted 10/14/2021 (updated 4/3/2024)
Presenters reviewed resources available to rural grantees through their respective agencies.
Posted 12/15/2020 (updated 4/3/2024)
Dr. Seale led a discussion on communicating OUD needs in your community, building MOUD practice capacity, and other considerations and lessons learned from his work with individuals in rural communities.
Posted 12/15/2020 (updated 4/3/2024)
Region 4 RCORP grantees share their experiences.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 9/1/2021 (updated 4/2/2024)